Efficacy and Safety of GSK3196165 Versus Placebo and Tofacitinib in Participants With Moderately to Severely Active Rheumatoid Arthritis Who Have an Inadequate Response to Conventional Synthetic (cs)/Biologic (b) Disease Modifying Anti-rheumatic Drugs (DMARDs)

Inclusion Criteria

• •\>=18 years of age
• •Has had RA for \>=6 months and was not diagnosed before 16 years of age
• •Has active disease, as defined by having both\*
• •* \>=6/68 tender/painful joint count (TJC), and
• •* \>=6/66 swollen joint count (SJC)
• •Has at least 1 bone erosion present on hand/wrist or foot radiographs
• •Has had an inadequate response to one or two of the csDMARDs:
• •* methotrexate (MTX) 15-25 mg/week\*\* oral or injected
• •* hydroxychloroquine up to 400 mg/day or chloroquine up to 250 mg/day
• •* sulfasalazine up to 3000 mg/day
• •* leflunomide up to 20 mg/day\*\*\*
• •* bucillamine up to 100 mg/day (or up to 300 mg/day if permitted per local requirement)
• •* iguratimod up to 50 mg/day
• •* If surgical treatment of a joint has been performed, that joint cannot be counted in the TJC or SJC.
• •* A lower dose of 7.5 mg/week is acceptable if reduced for reasons of intolerance to MTX or per local requirement.
• •* Concomitant use of leflunomide and methotrexate is not allowed, for safety reasons.